Quell Therapeutics signs a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize engineered TREG cell therapies for autoimmune diseases.

Quell will receive $85 million upfront and is eligible to receive over $2 billion for further development and commercialization milestones, if successful, plus tiered royalties.

More information:

https://quell-tx.com/quell-therapeutics-signs-a-collaboration-exclusive-option-and-license-agreement-with-astrazeneca-to-develop-manufacture-and-commercialize-engineered-treg-cell-therapies-for-autoimmune-diseases/